Insilico Medicine reports that its AI-designed drug candidate rentosertib reduced markers of biological aging in a small trial of 42 idiopathic pulmonary fibrosis patients, alongside previously observed improvements in lung function. Researchers applied six independent AI aging clocks to patients’ blood protein profiles. All predicted lower biological age for those receiving rentosertib versus placebo, with the strongest reductions appearing around week four in one dosing regimen. Experts call the findings encouraging but preliminary, highlighting the small sample, reliance on aging clocks, and need for trials in healthy volunteers. Rentosertib is already in Phase III testing for pulmonary fibrosis treatment approval.
This update represents a notable development in the Ai sector. Organizations and founders tracking this space should evaluate potential strategic and technical implications on their operations.